CAR T-cell immunotherapy of B-cell malignancy: the story so far

Leena Halim*, John Maher

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

37 Citations (Scopus)


Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell products by the United States Food and Drug Administration and European Medicines Agency. However, several issues associated with CAR T-cell treatment remain unresolved, such as the management of severe toxicities and the frequent occurrence of both antigen-positive and antigen-negative relapse. Nonetheless, pre-clinical research is advancing at an unprecedented pace to develop innovative solutions to address these issues. Herein, we summarise recent clinical developments and outcomes of CD19-targeted CAR T-cell immunotherapy and discuss emerging strategies that may further improve the success, safety and broadened applicability of this approach.

Original languageEnglish
JournalTherapeutic Advances in Vaccines and Immunotherapy
Publication statusPublished - 2020


  • B-cell
  • CD19
  • chimeric antigen receptor
  • clinical trial
  • leukaemia
  • lymphoma


Dive into the research topics of 'CAR T-cell immunotherapy of B-cell malignancy: the story so far'. Together they form a unique fingerprint.

Cite this